Cardiovascular in Biological Technology
Navigation Links
Cardiovascular in Biological Technology
... strategy and development programs, that include cardiovascular and wound healing biologics, into the emerging ... activities in the fields of wound healing and cardiovascular disease, the Company has access to a portfolio of ... therapeutic products for tissue repair and cardiovascular indications. In May 2009, Cardium announced ...
... monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared ... dose escalation study to assess the safety and cardiovascular effects of the implantation of MyoCell SDF-1 in ... test a combination gene and stem cell therapy for cardiovascular disease." The U.S. trial is expected to ...
... of life, and is associated with an increased cardiovascular mortality and morbidity. Prognosis of critical ... with at least twelve weeks follow up at the cardiovascular Research Foundation meeting on January 15, 2009 ... Associate Professor of Surgery and Director of cardiovascular and Regenerative Medicine at the University of ...
... implicated in cancer, ageing, obesity, diabetes, cardiovascular disease and toxicology," explained Dr. David ... in cancer, ageing, obesity, diabetes, cardiovascular disease and toxicology, Visit ... function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, ...
... For patients with a history of cardiovascular disease, or if the results of cardiac monitoring ... WARNINGS: Increased Mortality, Serious cardiovascular and Thromboembolic Events, and increased ... experienced greater risks for death and serious cardiovascular events when administered ...
... in Los Angeles, CA. Shah, a cardiologist and cardiovascular researcher, is a leading authority on apolipoproteins and cardiovascular health and the first researcher to demonstrate ... occurring human protein being developed as a cardiovascular therapy to stabilize and reverse atherosclerotic ...
... focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in ... number of product candidates targeting cardiovascular diseases to which Solvay Pharmaceuticals will ... our demonstrated capabilities and experience in cardiovascular drug development. We are pleased to partner with ...
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it ... trial of VIA-2291 conducted by the Company in cardiovascular disease. In addition to being generally ... is a new and leading-edge imaging technology for cardiovascular patients, that we feel will provide yet another ...
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...
... value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual ... value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual ... of vascular disease, can fill the gap in existing cardiovascular risk assessment and complement traditional risk ...
... are believed to increase the risk of developing cardiovascular disease and diabetes. BG Medicine's highly ... -- Systems Approach to Biomarker Research in cardiovascular Disease (SABRe CVD) -- may also aid ... in understanding, preventing, and treating cardiovascular diseases." Only information from ...
... greatly increases opportunities to engage in cardiovascular and sports medicine, ensuring that the CME ... Lawless is board certified in internal medicine, cardiovascular disease clinical lipidology¸ and sports medicine. ... to establish educational excellence not only in cardiovascular science, but also internal sports medicine for ...
... CML (carboxy-methyllysine), another potential cardiovascular risk marker. The holders of the Series B ... tests to diagnose and facilitate treatment of cardiovascular disease in people with diabetes. The Company has ... in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a ...
... in reducing the risk of suffering major cardiovascular events (combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal ... Health Promotion Research Group. European cardiovascular Disease Statistics 2008, ...
... data will determine the future of the 6R-BH4 cardiovascular program once all the studies are complete." ... to play a key protective role throughout the cardiovascular system and produces multiple positive effects, ... dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic ...
Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer
... have such a respected and passionate champion of cardiovascular health join our team," said Atherotech President ... medical education to advance the understanding of cardiovascular disease, yet much of his time is spent in the ... full range of medicine, including diabetes care, cardiovascular disease, hypertension, dyslipidemia, and bipolar ...... monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared ... dose escalation study to assess the safety and cardiovascular effects of the implantation of MyoCell SDF-1 in ... test a combination gene and stem cell therapy for cardiovascular disease." The U.S. trial is expected to ...
Regado Biosciences Expands Medical Advisory Board
... fields of cardiology, thrombosis/coagulation and cardiovascular surgery who advise the Company on its clinical ... Coordinating Centre for Global Collaborative cardiovascular Research) Richard C. Becker, MD , Professor of Medicine and Director of the cardiovascular Thrombosis Center, Duke Clinical Research ...VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...... of life, and is associated with an increased cardiovascular mortality and morbidity. Prognosis of critical ... with at least twelve weeks follow up at the cardiovascular Research Foundation meeting on January 15, 2009 ... Associate Professor of Surgery and Director of cardiovascular and Regenerative Medicine at the University of ...
iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
... director of the Gladstone Institute of cardiovascular Disease and professor at the University of ... disease and longer term into metabolic and cardiovascular diseases, as well as other therapeutic areas." ... is the director of the Gladstone Institute of cardiovascular Disease, a professor of the departments of ...CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
... expansion of both SonoSite's and CardioDynamics' cardiovascular platforms and benefit the customers, employees ... value and reducing healthcare system costs in cardiovascular disease management. CardioDynamics is the ... contributions in making ICG an important part of cardiovascular care for the over 12,000 physicians who use ICG ...VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
... the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...Regado Biosciences Establishes Medical Advisory Board
... of cardiology, thrombosis and coagulation, and cardiovascular surgery. These highly regarded leaders will ... Coordinating Centre for Global Collaborative cardiovascular Research) Richard C. Becker, MD , Professor of Medicine and Director of the cardiovascular Thrombosis Center, Duke Clinical Research ...... implicated in cancer, ageing, obesity, diabetes, cardiovascular disease and toxicology," explained Dr. David ... in cancer, ageing, obesity, diabetes, cardiovascular disease and toxicology, Visit ... function in obesity, diabetes, ageing, cancer, cardiovascular function and safety toxicity. Founded in 2001, ...
... For patients with a history of cardiovascular disease, or if the results of cardiac monitoring ... WARNINGS: Increased Mortality, Serious cardiovascular and Thromboembolic Events, and increased ... experienced greater risks for death and serious cardiovascular events when administered ...
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
... a Senior Investigator with the TIMI Study Group, cardiovascular Division, Department of Medicine, Brigham and ... reduced the risk of the combined endpoint of cardiovascular death, heart attack, or stroke by 19 percent (9.9 ... Health Promotion Research Group. European cardiovascular Disease Statistics 2008, ...... in Los Angeles, CA. Shah, a cardiologist and cardiovascular researcher, is a leading authority on apolipoproteins and cardiovascular health and the first researcher to demonstrate ... occurring human protein being developed as a cardiovascular therapy to stabilize and reverse atherosclerotic ...
... focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in ... number of product candidates targeting cardiovascular diseases to which Solvay Pharmaceuticals will ... our demonstrated capabilities and experience in cardiovascular drug development. We are pleased to partner with ...
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it ... trial of VIA-2291 conducted by the Company in cardiovascular disease. In addition to being generally ... is a new and leading-edge imaging technology for cardiovascular patients, that we feel will provide yet another ...
New Website Connects Physicians to Solve Challenging Cases and Share Experiences
... Forum Launch Interactive, Case-Based Website on cardiovascular Disease for Worldwide Learning and Collaboration ... a similar patient. That's why the Society for cardiovascular Angiography and Interventions (SCAI) and The ... worldwide collaboration among doctors who treat cardiovascular disease. Launched at SCAI's Annual Scientific ...Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
... DURATION-1 study and the meta-analysis of primary cardiovascular events across the BYETTA clinical database. ... the BYETTA database showed no increased risk of cardiovascular events associated with exenatide use. This ... outlined in the FDA's guidance for evaluating cardiovascular risk in type 2 diabetes agents. Components ...United Therapeutics Reports First Quarter 2009 Financial Results
... 2009 2008 Change Program: cardiovascular $11,418 $14,485 ... $21,076 (0.6)% Cardiovascular. cardiovascular expenses for the three months ended March 31, ... of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. ...BioMarin Announces First Quarter 2009 Financial Results
... in the second half of 2010. 6R-BH4 for cardiovascular indications: The investigator-sponsored Phase Ib ... a decision on the future of the 6R-BH4 cardiovascular program by the third quarter of 2009. ... Pompe Disease 3Q09: Decision on 6R-BH4 cardiovascular program 1Q10: Initiation of Phase I trial ...deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
... markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, ... most widely replicated genetic risk factors for cardiovascular and metabolic disease, and they provide a natural ... internal proprietary genetic discoveries in cardiovascular disease such as KIF6 and LPA, furthers Celera's ...VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that an ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...
Atherotech Unveils New Cardiometabolic Test Panels
... Test, has announced the addition of new cardiovascular and metabolic testing panels at ACC.09, the ... The company is also adding advanced and follow-up cardiovascular disease (CVD) risk profiles. "We're ... plus the new test panels. You get the complete cardiovascular and metabolic view." Atherotech ...... value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual ... value of VENDYS®, the new FDA-approved cardiovascular test, will be presented at the 2009 Annual ... of vascular disease, can fill the gap in existing cardiovascular risk assessment and complement traditional risk ...
VIA Pharmaceuticals Complies With NASDAQ Rules
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced, in ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ... compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and ...Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
... Large cardiovascular Outcomes Study To Be Initiated Manufacturing ... ) today announced that a meta-analysis of primary cardiovascular events across controlled clinical studies of ... injection database, showed no increased risk of cardiovascular events associated with exenatide use. This ...VIA Pharmaceuticals Secures Financing Up to $10.0 Million
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced it has ... in our lead program VIA-2291 for the treatment of cardiovascular disease caused by atherosclerosis, by targeting ... the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, ...... are believed to increase the risk of developing cardiovascular disease and diabetes. BG Medicine's highly ... -- Systems Approach to Biomarker Research in cardiovascular Disease (SABRe CVD) -- may also aid ... in understanding, preventing, and treating cardiovascular diseases." Only information from ...
Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
... of risk for heart disease, diabetes and other cardiovascular diseases. The new, clinically validated heart ... the apoB/apoAI ratio is superior to all other cardiovascular disease risk marker ratios." ApoAI is the ... diabetic patients, the apoB/apoAI ratio predicted cardiovascular disease and coronary heart disease events and ...... greatly increases opportunities to engage in cardiovascular and sports medicine, ensuring that the CME ... Lawless is board certified in internal medicine, cardiovascular disease clinical lipidology¸ and sports medicine. ... to establish educational excellence not only in cardiovascular science, but also internal sports medicine for ...
EPA Awards Lovelace Respiratory Research Institute $500,000 for Air Quality Research
... on air pollutant components as possible link to cardiovascular disease ALBUQUERQUE, N.M., March 4 ... health indicators, or "biomarkers" of cardiovascular disease caused by air pollution. Exposures to ... have been identified as a possible cause for cardiovascular disease in humans, but there is limited ...VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
... the development of compounds for the treatment of cardiovascular and metabolic disease, today announced the ... in Phase II development for the treatment of cardiovascular disease caused by atherosclerosis, targets ... the vessel wall as a critical step in combating cardiovascular disease and its complications, including heart ...... CML (carboxy-methyllysine), another potential cardiovascular risk marker. The holders of the Series B ... tests to diagnose and facilitate treatment of cardiovascular disease in people with diabetes. The Company has ... in identifying diabetic patients at high risk for cardiovascular complications. These patients may benefit from a ...
New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy
... are superior to synthetic HRT with greater cardiovascular benefits and reduced risk of breast cancer ... than an increased risk of breast cancer and cardiovascular disease." The review also showed that ... a reduced risk for breast cancer and superior cardiovascular protection. "While larger, randomized ...... in reducing the risk of suffering major cardiovascular events (combined endpoint of cardiovascular death, non-fatal heart attack or non-fatal ... Health Promotion Research Group. European cardiovascular Disease Statistics 2008, ...
VAP Test Demonstrates Value of Fish Oil in Reducing Heart Risk for Super Bowl Champs
... Steelers. Researchers assessed emerging cardiovascular risk factors, as found in the specialized VAP(R) ... of triglycerides are associated with diabetes and cardiovascular disease. These results suggest a strong benefit ... Dr. Joseph Maroon, said the VAP Test identifies cardiovascular risks that a routine cholesterol test cannot. By ...Cordex Pharma Forms Heart Failure Medical Advisory Board
... editorial on redox-nitric oxide balance in the cardiovascular system. Other members of the Medical ... School of Medicine . He is also the Chief of cardiovascular Medicine, Director of the Myocardial Biology ... the Cardiomyopathy Program and Co-Director of the cardiovascular Center at Boston Medical Center. Howard J. ...... data will determine the future of the 6R-BH4 cardiovascular program once all the studies are complete." ... to play a key protective role throughout the cardiovascular system and produces multiple positive effects, ... dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic ...
Traditional Risk Factors Often Miss Heart Disease Warning Signs
... The study is titled Prevalence of Emerging cardiovascular Risk Factors in Younger Individuals with a Family ... that, "The Framingham risk score underestimates cardiovascular risk in individuals with a family history of premature CHD, and screening for emerging cardiovascular risk factors may better assess CV ...Other ContentsstaphylococcusstaphylococcusdermatitisdermatitisdermatitisstarvationstarvationstarvationstentstentstentstentstentstenosisstenosissterilitysterilitysterilitysternumstillbirthstillbirthOther TagsIHCVonVonTRAPTRAPTRAPTRAPTRAPCoonHamHamHamHamHamrabrabrabrabrabrabrabScyTekOther Tagsbeads 2adjuvant 2adjuvant 3which 2which 3which 4which 5which 6which 7which 8which 9which 10improving 2improving 3improving 4improving 5improving 6improving 7improving 8going 2going 3going 4going 5going 6going 7going 8going 9going 10enters 2enters 3happens 2happens 3happens 4happens 5happens 6happens 7happens 8happens 9happens 10
(Date:11/24/2009)... New research on bacterial communities throughout...able temporal patterns, suggesting that scientists...ring climate change in the polar regions. The stud...National Academy of Sciences Early Edition, shows...ted synchronously over time, correlating with seas...
(Date:11/23/2009)... 2009 Applied mathematicians dissected the morpho...characteristic long leaf with a saddle-like arc mi...s. The simple cause of the lily,s fan-like shapeel...ferential growthwas revealed by using an equally s...i Liang, a postdoctoral student at Harvard,s Schoo...
(Date:11/23/2009)...uggests that a common oral bacterium may exacerbat...ls et al, "Unique Lipids from a Common Human Bacte... of Enhancing Autoimmunity," appears in the Decemb...y . , Multiple sclerosis (MS), a disease where t..., affects nearly 1 in 700 people in the United Sta...
Breaking Biology News(10 mins):Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2The cause behind the characteristic shape of a long leaf revealed 2Factors from common human bacteria may trigger multiple sclerosis 2Second hand smoking results in liver disease study finds 9877 1Second hand smoking results in liver disease study finds 9877 2Ritter Pharmaceuticals Hires Dr Howard Foyt as Executive Vice President Development 26 Chief Medical Officer 56849 1Ritter Pharmaceuticals Hires Dr Howard Foyt as Executive Vice President Development 26 Chief Medical Officer 56849 2ADA FDI World Dental Federation Observe World Oral Health Day 56846 1ADA FDI World Dental Federation Observe World Oral Health Day 56846 2(Date:11/25/2009)...mice, disks placed under the skin kill tumor cells...althDay News) -- A cancer vaccine delivered in a f...in mice, a new study reports. , The method uses...are loaded with tumor-specific antigens and implan...to attack tumors. The Harvard University scientist...
(Date:11/25/2009)... BioSpace.com, the premier r...unveiled the third edition of the BioForest™... Englewood, CO (Vocus) November 25, 2009 --...ce careers and information, unveiled the third edi...morning., , , , ,This regional campaign is a prom...
(Date:11/25/2009)..., SALTLAKECITY,Nov.25/PRNewswire/--dazzlesmile,...C www.optimalhealthscience.com havefileda67-pagefe...azoogle.com,Inc.,JesseWillms,FarendServicesLimited...ththeUnitedStatesDistrictCourtfortheDistrictofUtah...gofdazzlesmile(TM)brandedteethwhiteningproducts,vi...
(Date:11/25/2009)... HOUSTON - Two signaling pathways essential to nor... epidermal growth factor receptor (EGFR) pathways ...asion and metastasis, researchers from The Univers...n the Nov. 25 issue of Molecular Cell . , This ...naling components known to correlate with invasive...
(Date:11/25/2009)...This press release is available in French . , ,...nologies are about to enter the marketplace, thank...imited Partnership (Univalor) and Cognitive Sensin... based in Montreal. , Univalor, which commercial... its affiliated institutions, and CSI have announc...
Breaking Medicine News(10 mins):Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 2Health News:Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis 3Health News:Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries 2[2] Implantable Cancer Vaccine Shows Promise[1] BioSpace Showcases Leading Life-Science Companies in the Northwest[0] dazzlesmile Sues Epic Advertising and Jesse Willms[0] Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis[0] Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |